BackgroundA wireless motility capsule is a new method for ambulatory assessment of transit times and motility throughout the gastrointestinal tract. The objective of this study was to evaluate the ability of a wireless motility capsule to detect drug effects on gastric emptying time (GET) and gastric contractility.Methods15 healthy adults were administered in random order saline, erythromycin IV 150 mg, or morphine IV 0.05 mg/kg BW. Subjects ate a standard meal after each infusion, and subsequently ingested the motility capsule. Data were recorded for 8 hours, and the results were analyzed using the manufacturer’s software.ResultsGET was significantly faster after erythromycin than either saline or morphine. Morphine tended to delay emptying of the capsule compared to saline. There was a trend toward a greater frequency of gastric contractions with erythromycin and a reduced frequency of gastric contractions with morphine that did not reach statistical significance.ConclusionsA wireless motility capsule successfully detected acceleration of gastric emptying induced by erythromycin, and retardation of gastric motility caused by morphine. These results indicate that a wireless motility capsule is a promising technique to assess pharmacologic effects on gastric transit and contractility and aid in development of drugs for gastric motor disorders.
Hepatorenal syndrome (HRS) is a potentially reversible cause of acute renal failure that occurs in patients with hepatic failure resulting from advanced cirrhosis. It is characterized by impaired kidney function in the setting of normal renal parenchyma, alterations in cardiovascular function, splanchnic vasodilation, and overactivity of the sympathetic nervous and the renin‐angiotensin systems causing severe arterial vasoconstriction. Clinically, patients will present with the classic signs and symptoms of liver and renal failure, such as ascites, jaundice, coagulopathy, hepatic encephalopathy, and decreased urine output. Patients with cirrhosis are thought to have extreme circulatory dysfunction caused by portal hypertension‐induced release of vasodilators (primarily nitric oxide) into the splanchnic circulation, causing local vasodilation. Terlipressin is a synthetic long‐acting analogue of vasopressin in which lysine is substituted for arginine at position 8 and the N‐triglycyl residue. It has been shown to cause direct vasoconstriction of the systemic arteriolar and splanchnic vasculature. It affects the V1 vasopressin receptors of systemic vasculature more strongly than the V2 vasopressin receptors of the kidneys. Although it is not currently approved by the U.S. Food and Drug Administration, it has been widely studied and is currently being used in other countries for the treatment of HRS. Terlipressin is quickly emerging as a promising treatment of hepatorenal syndrome. Today its best use may be in improving renal function in preparation for liver transplantation, which has shown to reduce post‐transplant morbidity and mortality.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.